Cancer Drug Prices Could Plummet by 70% Under New Govt Cap
The Indian government plans to cap trade margins at 30% for non-scheduled anti-cancer drugs, potentially saving patients Rs 2,500 crore annually.
In a massive relief for patients fighting one of the most expensive diseases, the Indian government is preparing to slash the cost of anti-cancer medicines significantly. Official sources indicate that prices for these life-saving drugs could drop by as much as 70 per cent as the government moves to implement a strict cap on trade margins.
The proposed intervention aims to limit trade margins to a maximum of 30 per cent of the Maximum Retail Price (MRP) for all non-scheduled anti-cancer drugs. This move is designed to tackle the issue of excessive mark-ups that have historically made cancer treatment a financial nightmare for many families.
Broad Coverage for All Types of Medicines
Unlike previous regulations that might have been limited in scope, this new measure is expected to be incredibly comprehensive. The trade margin cap is intended to apply to:
- Branded and generic medicines
- Domestic and imported drugs
- Patented and non-patented anti-cancer medications
By including patented medicines in this scope, the government is targeting the most expensive segment of the oncology market, where costs have traditionally been highest.
Massive Savings for Patients
The financial impact of this decision is expected to be monumental. Beyond the immediate reduction in the cost of individual prescriptions, official sources estimate that the move could lead to annual savings of approximately Rs 2,500 crore for the public.
This initiative is a direct attempt to reduce the heavy out-of-pocket expenditure that cancer patients often face. It builds upon a successful 2019 intervention that saved roughly Rs 984 crore across 526 different brands, proving that price regulation can effectively make healthcare more accessible.
Final Decision Imminent
The government is currently in the final stages of deciding on the specific price cap. To ensure the decision is scientifically sound and does not affect the availability of drugs, a specialized committee has been formed. This committee includes oncologists who will provide expert medical insight before a final decision is reached.
The Department of Pharmaceuticals has already requested an analysis from the National Pharmaceutical Pricing Authority (NPPA) regarding trade margins on specific medicines. Looking ahead, the government intends to use this model as a blueprint, potentially extending similar price control processes to a wider range of cancer medicines and other critical drugs in the future.